Coleman Mark sold $1.4M of AXSM
Coleman Mark sold 6,000 shares of Axsome Therapeutics, Inc. (AXSM) at $230.30 ($1.38M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure may influence short-term trading sentiment, but the presence of a pre-arranged 10b5-1 plan typically lowers the informational content relative to unscheduled insider sales.
Market read
A dated insider sale at a stated price is disclosed after the fact; any effect is likely modest and short-lived.
What to watch
The article does not report any change in fundamentals, guidance, trial outcomes, or new contracts—so the trading impact should be treated as sentiment/positioning only.
Background
The article is an SEC Form 4 insider transaction disclosure for Axsome Therapeutics, reported via EDGAR.
Ticker impact
Axsome Therapeutics director Coleman Mark sold 6,000 shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low, likely limited to short-term sentiment/flow effects rather than a fundamental repricing.
The filing provides a specific sale price/date and confirms a pre-arranged 10b5-1 plan, which typically dampens interpretive value versus discretionary selling.
Market effects
Minimal; this is company-specific insider activity with no stated sector catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view.
Key entities
- issuerAxsome Therapeutics, Inc.
Subject of the insider transaction disclosure (Form 4).
- insiderColeman Mark
Director who sold 6,000 shares under an open-market sale code S.
